image: To schedule a meeting with Insilico team, please email to BD@insilico.com
Credit: Insilico Medicine
Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, will be exhibiting at the American Association for Cancer Research (AACR) Annual Meeting 2025 from April 25–30, 2025. The seasoned Insilico Business Development team led by Petrina Kamya, Ph.D, Global Head of AI Platforms & VP, Insilico Medicine Canada, and Michelle Chen, Ph.D, Chief Business Officer of Insilico Medicine, will be welcoming collaboration and industrial insight conversations at Booth #334, McCormick Place Convention Center, Chicago.
To maximize generative AI potential and foster scientific breakthroughs, Insilico Medicine considers academic publications as the key to knowledge democratization. During AACR 2025, Insilico is showcasing some of the most significant achievements among the 200+ peer-reviewed publications, including the AI-powered discovery of a potential cancer therapy strategy, published on Aging; a AI-driven CDK7 inhibitor with optimized druggability profiles published on Journal of Medicinal Chemistry; and innovative KRAS inhibitors enhanced by quantum computing algorithms published on Nature Biotechnology.
In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, laying the foundation for the commercially available Pharma.AI platform. Since 2021, Insilico has nominated 22 developmental/preclinical candidates (DC/PCC) with the help of Pharma.AI, and received IND approval for 10 molecules, providing novel solutions for areas including cancer therapy and immunology.
About Insilico Medicine
Insilico Medicine, a globally pioneering tech-bio company powered by generative AI, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating the technologies of AI and automation, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Ten molecules in Insilico's AI-driven pipeline portfolio have received IND clearance, with the most advanced being Rentosertib (formerly ISM001-055), a potentially first-in-class drug candidate for idiopathic pulmonary fibrosis, which has completed Phase 2a clinical studies with encouraging results. Additionally, Insilico is exploring exciting new frontiers empowered by AI and automated capabilities, including breakthroughs in aging research, sustainable chemistry, and agricultural innovation.
For more information, please visit www.insilico.com.